Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an effort to exhaust the possible benefit from that treatment.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.

[powerpress]

Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for  patients with advanced NSCLC, as well as whether smoking status factors into her approach.

[powerpress]